Markets:

Overview

News

Currencies

International

Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

45.57 +0.39 (+0.86%)

Streaming Delayed Price Updated: 12:08 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

February 26, 2025

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Via StockStory

Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham ↗

January 10, 2025

Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation.

Via Benzinga

A Preview Of Collegium Pharmaceutical's Earnings ↗

November 06, 2024

Via Benzinga

S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 05, 2024

Via Benzinga

Topics Stocks

The Analyst Landscape: 4 Takes On Collegium Pharmaceutical ↗

September 05, 2024

Via Benzinga

Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again? ↗

September 03, 2024

Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts ↗

August 09, 2024

Via Benzinga

Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews ↗

May 10, 2024

Via Benzinga

Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know ↗

April 11, 2024

Via Benzinga

Organon Stock Sees Relative Strength Rating Rise To 91 ↗

August 27, 2024

On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.

Via Investor's Business Daily

Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 20, 2024

On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.

Via Investor's Business Daily

COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals. ↗

August 06, 2024

COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

NASDAQ:COLL is an undervalued gem with solid fundamentals. ↗

July 16, 2024

COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying.

Via Chartmill

Dr. Reddy's Labs Stock Sees Improved Technical Strength ↗

June 28, 2024

On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.

Via Investor's Business Daily

Where Collegium Pharmaceutical Stands With Analysts ↗

February 23, 2024

Via Benzinga

Recap: Collegium Pharmaceutical Q4 Earnings ↗

February 22, 2024

Via Benzinga

Analyst Expectations For Collegium Pharmaceutical's Future ↗

February 02, 2024

Via Benzinga

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals. ↗

June 24, 2024

COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is an undervalued gem with solid fundamentals.

Via Chartmill

COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Why Collegium Pharmaceutical Shares Are Gaining Today ↗

January 03, 2024

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced FY24 financial

Via Benzinga

TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗

January 03, 2024

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a...

Via Benzinga

Topics Stocks

Recap: Collegium Pharmaceutical Q3 Earnings ↗

November 07, 2023

Via Benzinga

Needham Maintains Buy Rating for Collegium Pharmaceutical: Here's What You Need To Know ↗

August 25, 2023

Via Benzinga

Recap: Collegium Pharmaceutical Q1 Earnings ↗

May 04, 2023

Via Benzinga

Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday ↗

August 04, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Earnings Outlook For Collegium Pharmaceutical ↗

February 22, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 07, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 07, 2023

It's time to start the day with a breakdown of the biggest pre-market stock movers investors will want to watch on Tuesday!

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today